CD4-zeta gene-modified T cells

This is an autologous CAR-T cell therapy developed by the University of Pennsylvania for the treatment of HIV-1 infection. The therapy involves the ex vivo genetic modification of a patient's own CD4+ and CD8+ T cells with a chimeric antigen receptor (CAR) known as CD4-zeta (CD4ζ). This construct consists of the extracellular domain of the human CD4 molecule, which naturally binds to the HIV envelope protein (gp120), fused to the cytoplasmic signaling domain of the T-cell receptor zeta chain. Upon reinfusion, these engineered T cells can recognize and kill HIV-infected cells in an MHC-independent manner. Clinical studies have evaluated the safety, persistence, and trafficking of these cells, often in combination with interleukin-2 (IL-2) to support T-cell expansion and survival in patients on stable antiretroviral therapy (ART).

Other names

CD4-zeta CAR-T cellsCD-4-zeta CAR-T cellsCD 4-zeta CAR-T cellsAutologous CD4-zeta T cellsCD4-zeta T cellsCD-4-zeta T cellsCD 4-zeta T cells